Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 5/20 | 0.46 |
| ▸ | ENPP1 | P22413 | 3/20 | 0.40 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.40 |
| ▸ | CLK2 | P49760 | 1/20 | 0.40 |
| ▸ | LIMK1 | P53667 | 1/20 | 0.40 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.40 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.40 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 8/20 | 0.38 |
| ▸ | TP53 | P04637 | 5/20 | 0.38 |
| ▸ | NPC1 | O15118 | 5/20 | 0.38 |
| ▸ | RAB9A | P51151 | 5/20 | 0.38 |
| ▸ | MAPT | P10636 | 6/20 | 0.37 |
| ▸ | HPGD | P15428 | 5/20 | 0.37 |
| ▸ | MEN1 | O00255 | 4/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 4/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.37 |
| ▸ | LMNA | P02545 | 3/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7475534 | 0.79 | SMN1; SMN2 (0.47) | KDM4EHSD17B10CSNK1A1CLK2LIMK1 | |
| SCHEMBL7470768 | 0.79 | KDM4E (0.46) | KDM4EHSD17B10ENPP1CSNK1A1CLK2 | |
| SCHEMBL8044065 | 0.79 | HSD17B10 (0.47) | KDM4EHSD17B10ENPP1CSNK1A1CLK2 | |
| SCHEMBL7474031 | 0.79 | DYRK1A (0.51) | KDM4EHSD17B10CSNK1A1CLK2LIMK1 | |
| SCHEMBL7475747 | 0.78 | KDM4E (0.43) | KDM4EHSD17B10ENPP1CSNK1A1CLK2 | |
| SCHEMBL7477004 | 0.76 | KDM4E (0.51) | KDM4EHSD17B10SMN1; SMN2TP53NPC1 | |
| SCHEMBL7481507 | 0.76 | KDM4E (0.53) | KDM4EHSD17B10SMN1; SMN2RAB9AMAPT | |
| SCHEMBL7478966 | 0.75 | HSD17B10 (0.43) | KDM4EHSD17B10CSNK1A1CLK2LIMK1 | |
| SCHEMBL7474625 | 0.75 | HSD17B10 (0.46) | KDM4EHSD17B10SMN1; SMN2TP53NPC1 | |
| SCHEMBL7482369 | 0.75 | HSD17B10 (0.43) | KDM4EHSD17B10CSNK1A1CLK2LIMK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0883622-B1 | PROTON PUMP INHIBITOR | APOTEX INC (CA) | 2002-05-15 | — | — | EP | claimed |
| US-6093738-A | IMIDAZO(1,2-D)-THIADIAZOLE COMPOUNDS; PEPTIC ULCER TREATMENT | KARIMIAN KHASHAYAR (CA) | 2000-07-25 | — | — | US | claimed |
| CN-1216527-A | Method for scavenging mercaptan | APOTEX INC (CA) | 1999-05-12 | — | — | CN | claimed |
| EP-0883622-A1 | PROTON PUMP INHIBITOR | APOTEX INC. (CA) | 1998-12-16 | — | — | EP | claimed |
| US-5677302-A | Thiadiazole compounds useful as proton pump inhibitors | APOTEX INC. (CA) | 1997-10-14 | — | — | US | claimed |
| WO-1997031923-A1 | PROTON PUMP INHIBITOR | APOTEX INC. (CA) | 1997-09-04 | — | — | WO | claimed |
| US-20030225007-A1 | Sulfonamide derivatives of 3-substituted imidazol[1,2-d]-1,2,4-thiadiazoles and 3-substituted-[1,2,4] thiadiazolo[4,5-a] benzimidazole as inhibitors of fibrin cross-linking and transglutaminases | APOTEX INC. | 2003-12-04 | — | — | US | disclosed |
| EP-1348710-A1 | Sulfonamide derivatives of 3-substituted imidazo[1,2-D]-1,2,4-thiadiazoles and 3-substituted-[1,2,4]thiadiazolo[4,5-A]benzimidazole as inhibitors of fibrin cross-linking and transglutaminases | Apotex Inc. (CA) | 2003-10-01 | — | — | EP | disclosed |
| EP-0883622-B1 | PROTON PUMP INHIBITOR | APOTEX INC (CA) | 2002-05-15 | — | — | EP | disclosed |
| US-6114537-A | 1,2,4-THIADIAZOLE COMPOUND IS USEFUL FOR TRAPPING THIOL COMPOUNDS AND SELECTIVELY CHANGING THIOLS TO DISULFIDE COMPOUNDS | APOTEX INC. (CA) | 2000-09-05 | — | — | US | disclosed |
| US-6093738-A | IMIDAZO(1,2-D)-THIADIAZOLE COMPOUNDS; PEPTIC ULCER TREATMENT | KARIMIAN KHASHAYAR (CA) | 2000-07-25 | — | — | US | disclosed |
| EP-0883622-A1 | PROTON PUMP INHIBITOR | APOTEX INC. (CA) | 1998-12-16 | — | — | EP | disclosed |
| EP-0883606-A1 | PROCESS FOR SCAVENGING THIOLS | APOTEX INC. (CA) | 1998-12-16 | — | — | EP | disclosed |
| US-5677302-A | Thiadiazole compounds useful as proton pump inhibitors | APOTEX INC. (CA) | 1997-10-14 | — | — | US | disclosed |
| WO-1997031923-A1 | PROTON PUMP INHIBITOR | APOTEX INC. (CA) | 1997-09-04 | — | — | WO | disclosed |
| WO-1997031893-A1 | PROCESS FOR SCAVENGING THIOLS | APOTEX INC. (CA) | 1997-09-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030225007-A1 | Sulfonamide derivatives of 3-substituted imidazol[1,2-d]-1,2,4-thiadiazoles and 3-substituted-[1,2,4] thiadiazolo[4,5-a] benzimidazole as inhibitors of fibrin cross-linking and transglutaminases | PIGS, FGB, SERPINE1 | KDM4E 1493/4885HSD17B10 3346/4885ENPP1 2809/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.